14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
On August 9, 2019, Governor Andrew Cuomo signed into law an amendment to the New York State Human Ri...
Read More >
One practice that has plagued the insurance industry in recent years has been contractors soliciting...
Read More >
Our "2020 securities, shareholder, and M&A litigation outlook" provides our point of view on 2020, i...
Read More >
Non-compete restrictions for key stakeholders are common in shareholders' agreements. In Guest Servi...
Read More >
Not so long ago, in a galaxy not so far, far away, California passed Assembly Bill 5 (AB5), which to...
Read More >
On January 9, 2020, USCIS published a notice in the Federal Register to formally announce the implem...
Read More >